X
CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19). Learn More

Bicalutamide (Casodex®)

Common name: Bicalutamide
Brand name: Casodex®
 

What is Bicalutamide?

Bicalutamide is a non-steroidal anti-androgen used to treat advanced (metastatic) prostate cancer. It works by reducing the amount of testosterone in the body.  Bicalutamide may be given in combination with other hormonal therapies such as luteinizing hormone releasing hormone (LHRH) analogues or in the surgical removal of the testicles (castration).
 

How is Bicalutamide administered?

Bicalutamide is administered orally as a tablet.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received bicalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Constipation
  • Decreased libido
  • High blood pressure
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Loss of appetite
  • Nausea
  • Muscle weakness
  • Swelling of breasts
 

Is Bicalutamide covered in my province or territory?

Bicalutamide is covered by all provincial/territorial drug programs.


 
Last Reviewed: July 2017
Prostate Cancer Canada and Canadian Cancer Society








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation

February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation.
More

1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More


Click here for news archive